Bioscience Biz Artizan Inks Deal To Call Winchester Works Its New Home

NEW HAVEN, CT — Described as "cutting-edge biotechnology," Artizan Biosciences has signed a lease for a 10,000 square foot Class A lab and office space at Winchester Works, a technology and life sciences building anchored by New Haven’s Science Park.

Across the street from Yale’s Science Hill, Artizan Biosciences, a biotechnology company creating gut exclusive microbial metalloprotease inhibitors, will call Winchester Works its new home.

The company creates "a new class of transformative precision therapeutics that disrupt chronic inflammatory disease triggers."

According to the company "founded with preeminent immunobiology expertise from Yale University," Artizan’s "novel platform disrupts intestinal triggers of the inflammation process within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases." In addition to ARZC-001, Artizan is advancing additional late preclinical stage candidates for IBD and has a Parkinson’s disease therapeutic discovery and development program.

Winchester Office LLC comprises LMXD (an affiliated company of L+M Development Partners), Twining Properties, and the Goldman Sachs Urban Investment Group.

"We are incredibly excited to welcome Artizan Biosciences to our growing community," said Jake Pine, Senior Director at LMXD. "Companies like Artizan Biosciences play a critical role in advancing life-changing research and development and Winchester Works has been specifically designed to support these needs. The Science Park campus not only offers direct access to local talent and the region's top institutions but also provides tenants with the world-class lab and office space they need to be successful."

With 93,000 square feet of space already leased at Winchester Works, the addition of Artizan Biosciences underscores how the campus’ unique ecosystem continues to attract innovative and rapidly growing life sciences tenants. Currently located at 25 Science Park, Artizan Biosciences is moving to Winchester Works to accommodate its expanding research and development efforts. This state-of-the-art lab and office space will allow Artizan Biosciences to continue advancing its lead product candidate, ARZC-001, a novel, oral, gut-restricted potent small molecule inhibitor for the treatment of inflammatory bowel disease (IBD) toward the clinic. The space also allows Artizan to leverage additional possibilities using its proprietary IgA-SEQ™ technology platform as the company expands its treatment portfolio.

“As we continue to grow our staff and expand our clinical efforts, moving to Winchester Works allows us to accelerate our research efforts. We’re excited to remain in the burgeoning life sciences community of New Haven and close to the company’s beginnings at Yale University,” said Bridget Martell, M.A., M.D., Artizan’s President and CEO.